Tradestie Institutional Equity Comparison Engine
BIIB vs ADVM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BIIB Overall Edge
BIIB Captures Institutional Edge (4โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biogen Inc. Common Stock (BIIB) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BIIB trades at 15.6x Forward P/E with 23.5% operating margin (+10.6% YoY revenue) versus ADVM at N/M Forward P/E and 0.0% operating margin (-70.0% YoY). In options structure, BIIB sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against ADVM sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
BIIB
BIIB 15.6x vs ADVM N/M Fwd P/E
Growth & Margin Winner
BIIB
Op Margin 23.5% vs 0.0% ยท YoY +10.6% vs -70.0%
Momentum & Technical Winner
BIIB
1Y +53.4% vs -27.3% ยท 52W Pos 92% vs 55%
Options & Structure Winner
BIIB
CONSOLIDATION (6th %ile IV) vs UNCLASSIFIED (10th %ile IV)
BIIB
NASDAQ
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap
$37.0B
1M Return
+8.63%
1Y Return
+53.41%
Forward P/E
15.6x
Unified AI Score
50.2 / 100
HOLD
Tech 45.0
Fund 52.0
Flow 64.0
Mom 50.0
ADVM
NASDAQ
Adverum Biotechnologies, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.36
+4.06% 1D
Market Cap
$91.8M
1M Return
+1.87%
1Y Return
-27.33%
Forward P/E
N/M
Unified AI Score
62.4 / 100
BUY
Tech 60.0
Fund 57.0
Flow 62.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BIIB +53.41%
ADVM -27.33%
Spread: +7.19 pp (BIIB Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
BIIB TTM Op. Margin: 23.5%
ADVM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BIIB vs ADVM. Trailing 12-month operating profitability (BIIB 23.5% vs ADVM 0.0%) and valuation multiples (BIIB 15.6x vs ADVM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BIIB | ADVM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $37.0B | $91.8M | Larger Scale | BIIB |
| Trailing P/E Ratio Valuation | 109.9x | N/M | Lower Multiple | BIIB |
| Forward P/E Ratio Valuation | 15.6x | N/M | Lower Multiple | BIIB |
| Revenue Growth (YoY) Growth | +10.6% | -70.0% | Higher Growth | BIIB |
| Operating Margin (TTM) Profitability | 23.5% | 0.0% | Higher Margin | BIIB |
| Net Profit Margin Profitability | 3.4% | 0.0% | Higher Margin | BIIB |
| Return on Equity (ROE) Capital Efficiency | 1.9% | -417.8% | Higher ROE | BIIB |
| 52-Week Range Position Momentum | 92% ($160โ$261) | 55% ($2โ$6) | Stronger Trend | BIIB |
| Beta / 30D Volatility Risk Regime | 0.27ฮฒ ยท 36% Vol | 1.04ฮฒ ยท 17% Vol | Lower Realized Risk | ADVM |
| Unified Institutional Score Composite Signal | 50.2 / 100 (HOLD) | 62.4 / 100 (BUY) | Higher Composite | ADVM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BIIB vs ADVM Buy Guide
BIIB
CONSOLIDATION
17d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
6th %ile
IV Regime
Compressed (<25th %ile)
ADVM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
10th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BIIB nor ADVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.